Domarecki takes majority control of Poland's HiProMine with share buyout
What's the deal? Krzysztof Domarecki, HiProMineDealroom has a profile for this one. Try Dealroom →'s major shareholder, has crossed the 50% ownership threshold in the Polish agri-food and biotechnology company. Through his Luxembourg-based subsidiary WIGAR S.r.l.Dealroom has a profile for this one. Try Dealroom →, he acquired 117,223 shares on September 8, 2026, lifting his voting stake from 44.55% to 53.22%.
Why it matters: Domarecki now controls 719,650 shares and a majority of HiProMine's voting rights. That gives him decisive power over corporate decisions at the general meeting.
What each side does: HiProMine, based in Robakowo, operates in the agri-food and biotechnology sector and is listed as a public company under Polish securities regulations. It develops and commercialises new solutions, with its shares traded on an organised market. The deal value was not disclosed.
What changes: The shift consolidates strategic control in the hands of a single shareholder. It alters the balance of power and could shape HiProMine's long-term strategy and capital market perception. The company currently carries a market capitalisation of PLN64.1 million.
The signal: When a major backer moves from an anchor position to outright majority, governance dynamics tighten and minority investors lose leverage. For a small-cap biotech, that can mean faster, more unified decision-making — but it also concentrates the company's direction, and its risk, on one person.
